Peptides DB
Research-centric peptide and protocol reference hub

Tirzepatide record · updated 17h ago

Metabolic & appetiteSkin & aestheticsGrade A · human clinicalResearch use only
All 20 studiesJump to the evidenceCompare
What is Tirzepatide used for?

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has been investigated for its potential in managing type 2 diabetes and obesity. Its unique mechanism of action aims to enhance glycemic control and promote weight loss.

How it works: Dual GIP + GLP-1 receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Tirzepatide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 92 registered trials. It describes the research record, not a recommendation.

Identity
NameTirzepatide
Chain length
Molecular weight4,813 Da
FormulaC225H348N48O68
Structure typeNot established
ClassMetabolic
Research levelFDA Approved
Discovered byAdded before provenance tracking · 2025

Mass and formula from PubChem CID 166567236. No verified residue count for this compound.

Pharmacology
MechanismDual GIP + GLP-1 receptor agonist
RouteSubcutaneous injection
Half-life~5 days (≈120 h)
Time to peak8–72 h
DurationWeekly dosing
Extraction confidence0.95
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 30, 2026. How this works →
Research stats
Total studies20
Human / animal / cellular10 / 1 / 0
Highest trial phasePreclinical
Years covered2010–2026
Latest study2d ago
Publication history
20102026
Research funding
48 NIH projects · $30.7M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports2,412
Serious AEs in animal work
Community reports
Positive Neutral Negative
Records

Study register

20 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
From adiposity to multisystem morbidity: the case for weight loss as disease modification.
TakeawayNot reported in abstract.
2026Title only0.10
Insights from a double-blind, randomized, direct-to-participant intervention trial for Long COVID
Finding1,058 participants enrolled in 73 days.
Human2026Full text read0.80
Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy.
FindingBody weight reduced from 91.0 kg (IQR 75.0 - 106.0) to 82.8 kg (IQR 69.0 - 93.4; p<0.0001).
Human2026Full text read0.80
Clinical performance of monolithic and veneered zirconia three-unit posterior FDPs: A five-year multicenter randomized controlled trial.
FindingSurvival at 5 years was 94.7% for MONO-FDPs, 100% for FV-FDPs, and 100% for PV-FDPs.
Human2026Full text read0.90
Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study.
TakeawayNot reported in abstract.
Human2026Title only0.10
Early changes in body composition with tirzepatide in adults with obesity: a real-world BIA study.
FindingBody weight decreased by 8.75 kg (-8.18%, P < 0.001)
Human2026Full text read0.80
Tirzepatide and cardiovascular outcomes.
TakeawayNot reported in abstract.
2026Title only0.10
Genomic analyses identify nosocomial transmission of ST23 carbapenem-resistant hypervirulent &lt;i&gt;Klebsiella pneumoniae&lt;/i&gt; mediated by a conjugative IncFII&lt;sub&gt;K2&lt;/sub&gt; NDM-1 plasmid.
Finding0.37% ST23-K1 strains detected among 1069 CRKP bloodstream isolates.
Human2026Full text read0.80
Serious acute biliary reporting with glucagon-like peptide-1-based therapies versus sodium-glucose cotransporter-2 inhibitors in type 2 diabetes
Finding1.36 reporting odds ratio (95% CI 1.06-1.75; P = 0.013)
review2026Full text read0.80
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Finding90% (n=45/48) of PwO reported likelihood to recommend tirzepatide.
Human2026Full text read0.80
Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study.
FindingWeight loss of approximately 5.5 kg, n=28, P<0.001.
Human2026Full text read0.80
Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.
FindingCost per patient achieving HbA1c ≤6.5%, weight loss ≥15%, and no hypoglycemia was GBP 5,650 lower with tirzepatide 5 mg compared to semaglutide 1 mg.
review2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Tirzepatide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Tirzepatide is discussed should be drawn from it.